当前位置：
X-MOL 学术
›
Clin. Mol. Hepatol.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
TASL-TSOC Taiwan Position Statement for the Management of Metabolic Dysfunction-Associated Fatty Liver Disease and Cardiovascular Diseases.
Clinical and Molecular Hepatology ( IF 8.9 ) Pub Date : 2023-10-04 , DOI: 10.3350/cmh.2023.0315 Pin-Nan Cheng, Wen-Jone Chen, Charles Jia-Yin Hou, Chih-Lin Lin, Ming-Ling Chang, Chia-Chi Wang, Wei-Ting Chang, Chao-Yung Wang, Chun-Yen Lin, Chung-Lieh Hung, Cheng-Yuan Peng, Ming-Lung Yu, Ting-Hsing Chao, Jee-Fu Huang, Yi-Hsiang Huang, Chi-Yi Chen, Chern-En Chiang, Han-Chieh Lin, Yi-Heng Li, Tsung-Hsien Lin, Chia-Horng Kao, Tzung-Dau Wang, Ping-Yen Liu, Yen-Wen Wu, Chun-Jen Liu
Clinical and Molecular Hepatology ( IF 8.9 ) Pub Date : 2023-10-04 , DOI: 10.3350/cmh.2023.0315 Pin-Nan Cheng, Wen-Jone Chen, Charles Jia-Yin Hou, Chih-Lin Lin, Ming-Ling Chang, Chia-Chi Wang, Wei-Ting Chang, Chao-Yung Wang, Chun-Yen Lin, Chung-Lieh Hung, Cheng-Yuan Peng, Ming-Lung Yu, Ting-Hsing Chao, Jee-Fu Huang, Yi-Hsiang Huang, Chi-Yi Chen, Chern-En Chiang, Han-Chieh Lin, Yi-Heng Li, Tsung-Hsien Lin, Chia-Horng Kao, Tzung-Dau Wang, Ping-Yen Liu, Yen-Wen Wu, Chun-Jen Liu
Metabolic dysfunction associated fatty liver disease (MAFLD) is an increasingly important and common liver disease worldwide. The diagnosis of MAFLD is based on the presence of steatosis on image/histology/serum markers accompanied with presence of at least one of the three metabolic features that include overweight/obesity, type II diabetes mellitus, and metabolic risk factors. MAFLD is not only a liver disease but also a contributing or related factor of cardiovascular diseases (CVD) which lead to the major etiology of morbidity and mortality in patients with MAFLD. Hence, understanding the association of MAFLD and CVD, surveillance and risk stratification of MAFLD in patients with CVD, and current status of management of MAFLD are urgently needed for both hepatologist and cardiologist. The purpose of this Taiwan position statement is to review literature and provide suggestions that cover from epidemiology, etiology, risk factors, risk stratification, non-pharmacological intervention, and potential drug treatment of MAFLD, especially focusing on association with CVD.
更新日期：2023-10-04
京公网安备 11010802027423号